Tyvaso Inhalant
NDC Package 66302-206-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Other Packages
    4. Frequently Asked Questions

Package Information

Tyvaso (treprostinil) inhalants is a medication used to treat a type of high blood pressure in the lungs (pulmonary arterial hypertension). This formulation utilizes a inhalant delivery system. Marketed by United Therapeutics Corporation, this product is identified by NDC 66302-206 and is authorized under FDA application NDA022387.

Identification & Billing

NDC Package Code
66302-206-01
Package Description
1 BOX in 1 KIT / 28 AMPULE in 1 BOX / 2.9 mL in 1 AMPULE
Product Code
66302-206
11-Digit Billing Format
66302020601
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Tyvaso
Non-Proprietary Name
Treprostinil
Substance Name
Treprostinil
Dosage Form
Inhalant - A special class of inhalations consisting of a drug or combination of drugs, that by virtue of their high vapor pressure can be carried by an air current into the nasal passage where they exert their effect; the container from which the inhalant generally is administered is known as an inhaler.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
TREPROSTINIL 1.74 mg/2.9mL
Pharmacologic Class
Usage Information
This medication is used to treat a type of high blood pressure in the lungs (pulmonary arterial hypertension). Treprostinil helps to increase your ability to exercise and improves symptoms such as shortness of breath and tiredness. It works by relaxing and widening the blood vessels (arteries) in the lungs and other parts of the body so that blood can flow more easily. This medication belongs to a class of drugs known as vasodilators.

Regulatory & Marketing

Labeler Name
United Therapeutics Corporation
Product Type
Human Prescription Drug
FDA Application #
NDA022387
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
08-14-2009
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J7686
Source: ASP
Treprostinil, non-comp unit
HCPCS Dosage 1.74 MG
Units / Pkg 28

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (66302-206). Click a package code to view its specific billing and regulatory data.

66302-206-02
1 BOX in 1 KIT / 28 AMPULE in 1 BOX / 2.9 mL in 1 AMPULE
66302-206-03
4 AMPULE in 1 BOX / 2.9 mL in 1 AMPULE
66302-206-04
1 BOX in 1 KIT / 4 AMPULE in 1 BOX / 2.9 mL in 1 AMPULE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 66302-206-01 identifies a specific commercial package of 1 box in 1 kit / 28 ampule in 1 box / 2.9 ml in 1 ampule of Tyvaso, a human prescription drug labeled by United Therapeutics Corporation. This inhalant is formulated for oral use and contains treprostinil as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by United Therapeutics Corporation on August 14, 2009. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This medication is used to treat a type of high blood pressure in the lungs (pulmonary arterial hypertension). Treprostinil helps to increase your ability to exercise and improves symptoms such as shortness of breath and tiredness. It works by relaxing and widening the blood vessels (arteries) in the lungs and other parts of the body so that blood can flow more easily. This medication belongs to a class of drugs known as vasodilators.

How is this United Therapeutics Corporation product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 66302020601. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
66302-206-01
11-Digit CMS (5-4-2)
66302-0206-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.